Cargando…

Ataxin-3 Protein and RNA Toxicity in Spinocerebellar Ataxia Type 3: Current Insights and Emerging Therapeutic Strategies

Ataxin-3 is a ubiquitously expressed deubiqutinating enzyme with important functions in the proteasomal protein degradation pathway and regulation of transcription. The C-terminus of the ataxin-3 protein contains a polyglutamine (PolyQ) region that, when mutationally expanded to over 52 glutamines,...

Descripción completa

Detalles Bibliográficos
Autores principales:	Evers, Melvin M., Toonen, Lodewijk J. A., van Roon-Mom, Willeke M. C.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer US 2013
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4012159/ https://www.ncbi.nlm.nih.gov/pubmed/24293103 http://dx.doi.org/10.1007/s12035-013-8596-2

Ejemplares similares

Genetics, Mechanisms, and Therapeutic Progress in Polyglutamine Spinocerebellar Ataxias
por: Buijsen, Ronald A.M., et al.
Publicado: (2019)

Antisense Oligonucleotide-Mediated Removal of the Polyglutamine Repeat in Spinocerebellar Ataxia Type 3 Mice
por: Toonen, Lodewijk J.A., et al.
Publicado: (2017)

Transcriptional profiling and biomarker identification reveal tissue specific effects of expanded ataxin-3 in a spinocerebellar ataxia type 3 mouse model
por: Toonen, Lodewijk J. A., et al.
Publicado: (2018)

Antisense oligonucleotide-mediated exon skipping as a strategy to reduce proteolytic cleavage of ataxin-3
por: Toonen, Lodewijk J. A., et al.
Publicado: (2016)

Therapeutic Strategies for Spinocerebellar Ataxia Type 1
por: Kerkhof, Laurie M. C., et al.
Publicado: (2023)

Ataxin-3 phosphorylation decreases neuronal defects in spinocerebellar ataxia type 3 models
por: Matos, Carlos A., et al.
Publicado: (2016)

Autophagy induction reduces mutant ataxin-3 levels and toxicity in a mouse model of spinocerebellar ataxia type 3
por: Menzies, Fiona M., et al.
Publicado: (2010)

Human Induced Pluripotent Stem Cell-Based Modelling of Spinocerebellar Ataxias
por: Hommersom, Marina P., et al.
Publicado: (2021)

Urine levels of the polyglutamine ataxin-3 protein are elevated in patients with spinocerebellar ataxia type 3
por: Koike, Yuka, et al.
Publicado: (2021)

Ubiquitin-binding site 1 of pathogenic ataxin-3 regulates its toxicity in Drosophila models of Spinocerebellar Ataxia Type 3
por: Prifti, Matthew V., et al.
Publicado: (2023)

Ataxin-3, The Spinocerebellar Ataxia Type 3 Neurodegenerative Disorder Protein, Affects Mast Cell Functions
por: Sowa, Anna S., et al.
Publicado: (2022)

Targeting the VCP-binding motif of ataxin-3 improves phenotypes in Drosophila models of Spinocerebellar Ataxia Type 3
por: Johnson, Sean L., et al.
Publicado: (2021)

Histone deacetylase-3 interacts with ataxin-7 and is altered in a spinocerebellar ataxia type 7 mouse model
por: Duncan, Carlotta E, et al.
Publicado: (2013)

Cerebellar Soluble Mutant Ataxin-3 Level Decreases during Disease Progression in Spinocerebellar Ataxia Type 3 Mice
por: Nguyen, Huu Phuc, et al.
Publicado: (2013)

Identification of the ataxin-1 interaction network and its impact on spinocerebellar ataxia type 1
por: Chen, Jiu-Ming, et al.
Publicado: (2022)

miRNA-Mediated Knockdown of ATXN3 Alleviates Molecular Disease Hallmarks in a Mouse Model for Spinocerebellar Ataxia Type 3
por: Nobre, Rui Jorge, et al.
Publicado: (2022)

Partial Loss of Ataxin-1 Function Contributes to Transcriptional Dysregulation in Spinocerebellar Ataxia Type 1 Pathogenesis
por: Crespo-Barreto, Juan, et al.
Publicado: (2010)

The potential value of disease-modifying therapy in patients with spinocerebellar ataxia type 1: an early health economic modeling study
por: van Prooije, Teije, et al.
Publicado: (2023)

Mutant Ataxin-2 Expression in Aged Animals Aggravates Neuropathological Features Associated with Spinocerebellar Ataxia Type 2
por: Afonso, Inês T., et al.
Publicado: (2022)

Correction to: The potential value of disease-modifying therapy in patients with spinocerebellar ataxia type 1: an early health economic modeling study
por: van Prooije, Teije, et al.
Publicado: (2023)

Autophagy in Spinocerebellar Ataxia Type 3: From Pathogenesis to Therapeutics
por: Paulino, Rodrigo, et al.
Publicado: (2023)

TR-FRET-Based Immunoassay to Measure Ataxin-2 as a Target Engagement Marker in Spinocerebellar Ataxia Type 2
por: Bux, Jessica, et al.
Publicado: (2023)

Axonal inclusions in spinocerebellar ataxia type 3
por: Seidel, Kay, et al.
Publicado: (2010)

Frequency of Spinocerebellar Ataxia type 1, 2, 3,6 and 7 and clinical profile of Spinocerebellar Ataxia type 3 in Malaysia
por: Mohamed Ibrahim, Norlinah, et al.
Publicado: (2020)

The cerebral metabolic topography of spinocerebellar ataxia type 3
por: Meles, Sanne K., et al.
Publicado: (2018)

Cell-based therapeutic strategies for treatment of spinocerebellar ataxias: an update
por: Correia, Joana Sofia, et al.
Publicado: (2022)

Ataxin-1 oligomers induce local spread of pathology and decreasing them by passive immunization slows Spinocerebellar ataxia type 1 phenotypes
por: Lasagna-Reeves, Cristian A, et al.
Publicado: (2015)

Indirect Negative Effect of Mutant Ataxin-1 on Short- and Long-Term Synaptic Plasticity in Mouse Models of Spinocerebellar Ataxia Type 1
por: Shuvaev, Anton N., et al.
Publicado: (2022)

An understanding of spinocerebellar ataxia
por: Ramachandra, N.B., et al.
Publicado: (2015)

Parkinsonism in Spinocerebellar Ataxia
por: Park, Hyeyoung, et al.
Publicado: (2015)

Spinocerebellar ataxia: an update
por: Sullivan, Roisin, et al.
Publicado: (2018)

Expanded ataxin-7 cause toxicity by inducing ROS production from NADPH oxidase complexes in a stable inducible Spinocerebellar ataxia type 7 (SCA7) model
por: Ajayi, Abiodun, et al.
Publicado: (2012)

Postural Tremor and Ataxia Progression in Spinocerebellar Ataxias
por: Gan, Shi-Rui, et al.
Publicado: (2017)

Current understanding of the role of microRNAs in spinocerebellar ataxias
por: Koscianska, Edyta, et al.
Publicado: (2014)

Supratentorial and Infratentorial Lesions in Spinocerebellar Ataxia Type 3
por: Wang, Po-Shan, et al.
Publicado: (2020)

Abnormal eye movements in spinocerebellar ataxia type 3
por: Lin, Junyu, et al.
Publicado: (2021)

Intracerebroventricular Administration of a 2′-O-Methyl Phosphorothioate Antisense Oligonucleotide Results in Activation of the Innate Immune System in Mouse Brain
por: Toonen, Lodewijk J.A., et al.
Publicado: (2018)

Stage-dependent biomarker changes in spinocerebellar ataxia type 3
por: Faber, Jennifer, et al.
Publicado: (2023)

Neural correlates of ataxia severity in spinocerebellar ataxia type 3/Machado-Joseph disease
por: Hernandez-Castillo, Carlos R., et al.
Publicado: (2017)

Cell biology of spinocerebellar ataxia
por: Orr, Harry T.
Publicado: (2012)

Cannot write session to /tmp/vufind_sessions/sess_v9uk1r0cfup3c6et7531ljqo3v